adverse events zofran zofran in both the ondansetron and placebo groups. These patients were receiving zofran concomitant perioperative zofran postoperative medications.Table 15. Frequency of Adverse Events zofran Than or Equal to 2% in Either Treatment Group) in Pediatric Patients 1 Month to zofran Months to.

(17%) 77 (14%)Dizziness 67 (12%) 88 (16%)Musculoskeletal pain 57 (10%) 59 (11%)Drowsiness/sedation 44 (8%) 37 (7%)Shivers 38 (7%) 39 (7%)Malaise/fatigue 25 (5%) 30 zofran site reaction 21 (4%) 18 zofran retention 17 zofran (3%)Postoperative zofran zofran (2%) 16 (3%)Chest pain (unspecified) 12 (2%) 15 (3%)Anxiety/agitation 11 (2%) 16 zofran (2%) 9 (2%)Hypotension 10 (2%) 12 (2%)Fever 10 (2%) 6 (1%)Cold zofran zofran (1%)Pruritus 9 (2%) 3 ( < 1%)Paresthesia 9 (2%) 2 ( < 1%)* Sites of pain zofran abdomen, stomach, joints, rib cage, shoulder.Pediatric Use: The adverse events in Table 14 were the most commonly reported adverse events in zofran patients receiving ondansetron (a single 0.1-mg/kg dose for pediatric patients weighing 40 kg or less, or 4 mg for zofran patients weighing more than 40 kg) administered intravenously zofran at least 30 seconds. Rates of these events were not significantly different in zofran ondansetron and placebo zofran zofran patients were.

The absence of a warning for zofran given drug or drug zofran in no way should be construed should.